AnaptysBio Inc has a consensus price target of $35.67, established from looking at the 23 latest analyst ratings. The last 3 analyst ratings were released from Wedbush, BTIG, and Stifel on March 12, 2024, February 26, 2024, and February 21, 2024. With an average price target of $35 between Wedbush, BTIG, and Stifel, there's an implied 59.60% upside for AnaptysBio Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/12/2024 | ANAB | Buy Now | AnaptysBio | $21.93 | — | Wedbush | David Nierengarten | $20 → $34 | Upgrade | Neutral → Outperform | Get Alert |
02/26/2024 | ANAB | Buy Now | AnaptysBio | $21.93 | 150.8% | BTIG | Julian Harrison | → $55 | Initiates | → Buy | Get Alert |
02/21/2024 | ANAB | Buy Now | AnaptysBio | $21.93 | 128% | Stifel | Alex Schwartz | → $50 | Initiates | → Buy | Get Alert |
02/16/2024 | ANAB | Buy Now | AnaptysBio | $21.93 | 264.8% | Piper Sandler | Yasmeen Rahimi | → $80 | Initiates | → Overweight | Get Alert |
11/29/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | -8.8% | Wedbush | David Nierengarten | → $20 | Reiterates | Neutral → Neutral | Get Alert |
11/03/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | -8.8% | Wedbush | David Nierengarten | $18 → $20 | Maintains | Neutral | Get Alert |
11/02/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | -4.24% | UBS | Eliana Merle | $28 → $21 | Maintains | Neutral | Get Alert |
08/08/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | 18.56% | Wedbush | David Nierengarten | $29 → $26 | Maintains | Neutral | Get Alert |
05/22/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | 36.8% | JP Morgan | Anupam Rama | $31 → $30 | Upgrade | Underweight → Neutral | Get Alert |
05/12/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | 32.24% | Wedbush | David Nierengarten | → $29 | Reiterates | Neutral → Neutral | Get Alert |
05/12/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | 105.2% | Guggenheim | Yatin Suneja | $44 → $45 | Maintains | Buy | Get Alert |
04/12/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | 41.36% | JP Morgan | Anupam Rama | $32 → $31 | Maintains | Underweight | Get Alert |
01/06/2023 | ANAB | Buy Now | AnaptysBio | $21.93 | — | Raymond James | Timur Ivannikov | — | Downgrade | Outperform → Market Perform | Get Alert |
11/18/2022 | ANAB | Buy Now | AnaptysBio | $21.93 | 45.92% | JP Morgan | Anupam Rama | $24 → $32 | Maintains | Underweight | Get Alert |
11/09/2022 | ANAB | Buy Now | AnaptysBio | $21.93 | 73.28% | Raymond James | Steven Seedhouse | $30 → $38 | Maintains | Outperform | Get Alert |
11/01/2022 | ANAB | Buy Now | AnaptysBio | $21.93 | — | Guggenheim | Yatin Suneja | — | Upgrade | Neutral → Buy | Get Alert |
09/19/2022 | ANAB | Buy Now | AnaptysBio | $21.93 | 59.6% | HC Wainwright & Co. | Gobind Singh | → $35 | Assumes | → Buy | Get Alert |
09/13/2022 | ANAB | Buy Now | AnaptysBio | $21.93 | 27.68% | Truist Securities | John Lee | $50 → $28 | Downgrade | Buy → Hold | Get Alert |
09/01/2022 | ANAB | Buy Now | AnaptysBio | $21.93 | 59.6% | Raymond James | Steven Seedhouse | → $35 | Initiates | → Outperform | Get Alert |
The latest price target for AnaptysBio (NASDAQ: ANAB) was reported by Wedbush on March 12, 2024. The analyst firm set a price target for $0.00 expecting ANAB to fall to within 12 months (a possible -100.00% downside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for AnaptysBio (NASDAQ: ANAB) was provided by Wedbush, and AnaptysBio upgraded their outperform rating.
The last upgrade for AnaptysBio Inc happened on March 12, 2024 when Wedbush raised their price target to N/A. Wedbush previously had a neutral for AnaptysBio Inc.
The last downgrade for AnaptysBio Inc happened on January 6, 2023 when Raymond James changed their price target from N/A to N/A for AnaptysBio Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AnaptysBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AnaptysBio was filed on March 12, 2024 so you should expect the next rating to be made available sometime around March 12, 2025.
While ratings are subjective and will change, the latest AnaptysBio (ANAB) rating was a upgraded with a price target of $0.00 to $0.00. The current price AnaptysBio (ANAB) is trading at is $21.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.